New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
Rhea-AI Summary
Telix (ASX/NASDAQ: TLX) announced a new independent analysis of Phase 3 ZIRCON data published in European Urology showing TLX250-Px (Zircaix, 89Zr-girentuximab) PET/CT was highly predictive of renal malignancy across subtypes. Reported metrics: PPV 98% (95% CI 96–99), sensitivity 82% (95% CI 82–90), and specificity 87% (95% CI 81–93). The exploratory analysis suggests utility beyond clear cell RCC (ccRCC), including potential roles in managing non-clear cell RCC, but these analyses were exploratory and were not the basis of the company’s BLA, which focuses on ccRCC detection.
AI-generated analysis. Not financial advice.
Positive
- PPV 98% for PET-positive renal lesions
- Sensitivity 82% for detecting renal malignancy
- Specificity 87% distinguishing malignant from benign masses
- Evidence supports potential use beyond ccRCC into nccRCC management
Negative
- Findings are exploratory and not the basis of the TLX250-Px BLA
- ZIRCON was designed to address ccRCC, limiting definitive regulatory claims for nccRCC
News Market Reaction – TLX
On the day this news was published, TLX declined 0.99%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TLX gained 2.36% while close peers showed mixed, mostly modest moves (e.g., RARE +0.49%, APLS +0.04%, LGND +0.83%, MLTX +5.15%, ZLAB -0.75%). No peer momentum or same-day peer news was flagged, suggesting a stock-specific response to the TLX250-Px publication.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Phase 2 trial data | Positive | +5.5% | OPTIMAL-PSMA Phase 2 data for TLX597-Tx supporting dose intensification potential. |
| Apr 27 | Educational webinar | Neutral | +0.4% | Announcement of PSMA therapy webinar covering TLX597-Tx portfolio approach. |
| Apr 21 | Conference selection | Positive | +1.2% | ProstACT Global Phase 3 Part 1 safety data selected as ASCO 2026 late-breaking abstract. |
| Apr 14 | Phase 3 trial start | Positive | -0.4% | First patient dosed in Phase 3 IPAX-BrIGHT trial of TLX101-Tx for glioblastoma. |
| Apr 13 | Strategic collaboration | Positive | +6.6% | 50/50 radiopharma collaboration with Regeneron including upfront and milestone economics. |
Recent Telix news, especially on collaborations and clinical progress, has more often aligned with positive share moves, with only one noted divergence on a Phase 3 initiation update.
Over the last month, Telix reported multiple clinical and strategic milestones. A radiopharma collaboration with Regeneron including US$40 million upfront and up to US$2.1 billion in milestones saw a 6.64% gain. Phase 2 OPTIMAL-PSMA data and an ASCO 2026 late-breaking selection for ProstACT Global Part 1 also coincided with positive moves. First dosing in the Phase 3 IPAX-BrIGHT glioblastoma trial produced a minor -0.37% reaction, showing one divergence. The current TLX250-Px kidney cancer imaging publication adds to this stream of oncology-focused progress.
Market Pulse Summary
This announcement highlights exploratory Phase 3 ZIRCON data showing TLX250-Px PET/CT achieved a positive predictive value of 98%, with sensitivity of 82% and specificity of 87% across renal cancer subtypes. These findings extend beyond ccRCC but were not the basis of the TLX250-Px BLA, which focuses on primary ccRCC. Recent history shows Telix steadily adding clinical and partnership milestones, so investors may watch for regulatory decisions, broader renal indications, and further outcome data to gauge long-term impact.
Key Terms
pet/ct medical
carbonic anhydrase ix medical
positive predictive value medical
specificity medical
non-clear cell renal cell carcinoma medical
phase 3 medical
biologics license application regulatory
AI-generated analysis. Not financial advice.
MELBOURNE, Australia and INDIANAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology1, demonstrating that TLX250-Px (Zircaix®2, 89Zr-girentuximab) PET/CT3 imaging may be highly predictive of renal malignancy across all subtypes, not limited to clear cell renal cell carcinoma (ccRCC).
Recognizing that carbonic anhydrase IX (CAIX) expression is also observed in other renal cancer subtypes4, this subsequent analysis conducted by international investigators who participated in ZIRCON Phase 3 trial5, evaluated centrally reviewed imaging and pathology data to explore whether tracer uptake in renal masses correlated with malignancy beyond ccRCC.
The analysis demonstrated that positive PET findings were highly predictive of malignancy overall, including in non-clear cell renal cell carcinoma (nccRCC), with a reported positive predictive value (PPV) of
Aboubacar Kaba, MD, urologist at the University of California, Los Angeles and corresponding author, commented: “This analysis shows that when TLX250-Px PET/CT is positive, it is highly predictive of renal malignancy, including beyond ccRCC. Thus, the utility of this test may be important in distinguishing more hypoxic, and therefore, aggressive disease from indolent tumors with clear treatment implications. This may provide an additional tool to aid in risk stratifying or guiding patient and clinician decisions in the treatment of renal masses.”
Dr. David N. Cade, Group Chief Medical Officer at Telix, added: “Publication of these data in European Urology reflects the scientific strength of the ZIRCON trial and the robustness of its central imaging and pathology review. While ZIRCON was designed to address ccRCC, this analysis supports continued evaluation of TLX250-Px PET imaging across a broader spectrum of renal malignancies, with potential application in the management of patients with non-clear cell RCC. Furthermore, essentially all false-positives for ccRCC in the ZIRCON study have now been shown to be other malignant kidney cancer subtypes, reducing the risk of overtreatment and further supporting clinical adoption.”
The full paper is available at: https://www.europeanurology.com/article/S0302-2838(26)02037-3/fulltext.
These findings are based on exploratory analyses and were not the basis of Telix’s Biologics License Application (BLA) submission for TLX250-Px, which focuses exclusively on detection of ccRCC in primary renal masses.
About TLX250-Px
TLX250-Px is a PET imaging candidate under development for the diagnosis and characterization of ccRCC, and included in leading international guidelines for renal imaging6. It works by specifically binding to carbonic anhydrase IX (CAIX), a validated target protein expressed on >
Telix's pivotal Phase 3 ZIRCON trial evaluating TLX250-Px in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing
ZIRCON-X, a noninterventional, prospective, post hoc study using imaging data from ZIRCON, found that almost half of all patients (
For more on TLX250-Px and Telix's theranostic kidney cancer program, click here.
TLX250-Px has not received a marketing authorization in any jurisdiction.
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
| Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com | Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com | Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com |
Media Contact
Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
_______________________________________
1 Kaba et al. Eur Urol. 2026: https://doi.org/10.1016/j.eururo.2026.03.003
2 Brand name subject to final regulatory approval.
3 Positron emission tomography/computed tomography.
4 Baniak et al. Histopathology. 2020; Büscheck et al. Urol Oncol. 2018. Klatte et al. ClinCancer Res Off J Am AssocCancerRes. 2009.
5 Zirconium in Renal Cancer Oncology, ClinicalTrials.gov ID: NCT03849118.
6 SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization (October 2025), available at: https://jnm.snmjournals.org/content/early/2025/10/09/jnumed.125.271332.abstract
7 Stillebroer et al. Eur Urol. 2010.
8 Telix ASX disclosures November 7, 2022. Shuch et al. Lancet Oncology. 2024.
